Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of
allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for
grade 3-4 aGVHD is systemic glucocorticoid. However, there is no recognized second-line
treatment for grade 3-4 steroid-resistant aGVHD (SR-aGVHD). The investigators try to observe
the efficacy and safety of early application of anti-CD25 monoclonal antibody(basiliximab)
combined with ruxotilinib in the treatment of severe SR-aGVHD.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Huai'an Second People's Hospital Soochow Hopes Hematonosis Hospital